Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
An article in the June issue of the Canadian Urological Association Journal offers preliminary evidence from a randomized clinical trial that men treated for 6 months with a short-acting LHRH agonist may recover normal serum testosterone (T) levels faster than those treated for the same time with a long-acting LHRH agonist.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: LHRH agonist, long-acting, recovery, serum, short-acting, testosterone | 2 Comments »
An article in the May issue of BJU International has proposed establishment of an international data registry as being “the quickest way” to establish basic data on the risks related to testosterone replacement therapy in men with untreated prostate cancer.
Filed under: Living with Prostate Cancer, Management, Risk, Treatment | Tagged: hypogonadism, risk, serum, T, testosterone | Leave a Comment »
A few weeks ago, a Letter to the Editor in the New England Journal of Medicine focused on the significance of castrate levels of serum testosterone (serum T) in men being treated with LHRH agonists for advanced forms of prostate cancer.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation therapy, serum, survival, T, testosterone | 3 Comments »
A paper in a forthcoming issue of European Urology recommends strongly that clinicians should monitor serum testosterone (serum T) levels during androgen-deprivation therapy (ADT) in men with prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation therapy, serum, serum T, testosterone | 2 Comments »
And in a report in the Los Angeles Times “Booster Shots” blog, “Men who are infected with the sexually transmitted bacterium Trichomonas vaginalis have a slightly increased risk of developing prostate cancer and double the normal risk of developing the aggressive form of the disease that spreads throughout the body.”
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Uncategorized | Tagged: risk, serum, T. vaginalis | Leave a Comment »
In yet another example of the “maybe or maybe not” world of what helps to trigger increased risk for prostate cancer, we can now place serum calcium levels. Some recent studies (e.g., Skinner and Schwartz) have suggested an association between high levels of serum calcium and a high risk of prostate cancer death. Now an [...]
Filed under: Diagnosis, Risk | Tagged: calcium, risk, serum | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site